Phase II Study of Lonidamine in Cancer Patients
| Autor: | Robert Leclaire, Besner Jg, Michele Deschamps, Attilio de Sanctis, Pierre Gervais, Pierre R. Band |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
Male Cancer Research Indazoles Time Factors Phases of clinical research Antineoplastic Agents Anorexia Pharmacology chemistry.chemical_compound Breast cancer Prednisone Neoplasms Humans Medicine Aged business.industry Muscles Hyperesthesia Lonidamine Cancer General Medicine Middle Aged medicine.disease Oncology chemistry Vomiting Drug Evaluation Pyrazoles Female medicine.symptom business Digestive System medicine.drug |
| Zdroj: | Oncology. 41:66-68 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000225889 |
| Popis: | 12 patients with metastatic cancer were treated with the substituted indazole carboxylic acid Lonidamine at oral daily doses of 270 mg/m2. Toxicity, consisting mainly of myalgias, somnolence, hyperesthesia, anorexia and vomiting, generally decreased or disappeared over time despite continuing drug administration at unmodified dosage. Myalgias and hyperesthesias were markedly relieved with prednisone 5 mg twice daily. No laboratory abnormalities were seen. Partial responses were observed in a patient with hypernephroma and in a patient with breast cancer. Disease-oriented phase II studies with this new anticancer agent are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|